MicroTech Medical (Hangzhou) Co., Ltd. Class H (HK:2235) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MicroTech Medical (Hangzhou) Co., Ltd. reported a robust 36.1% increase in operating revenue for the first half of 2024, reaching RMB 150.8 million, with significant contributions from the successful launch of their new CGMS product, AiDEX X. Despite these gains, the company experienced a net loss of RMB 37.7 million, a 102.2% increase from the previous year, mainly due to higher selling expenses associated with the new product launch. However, the company successfully reduced administrative expenses by 12.7% and maintains a strong cash reserve of RMB 1.81 billion.
For further insights into HK:2235 stock, check out TipRanks’ Stock Analysis page.